Literature DB >> 23828443

Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.

Jörg B Engel1, Arnd Honig, Michaela Kapp, Jens C Hahne, Susanne R Meyer, Johannes Dietl, Sabine E Segerer.   

Abstract

PURPOSE: Triple negative breast cancers (TNBC) are associated with an adverse outcome, although these tumors are sensitive to chemotherapy. In part, this phenomenon could be caused by tumor immune escape. The current study investigates immunogenicity of TNBC cells in vitro and the presence of immunosuppressive factors in the tumor microenvironment (pAKT and B7H1 expression, infiltration with regulatory T cells, [Tregs]).
METHODS: Natural killer (NK)-cell induced lysis was evaluated in estrogen receptor (ER) positive MCF 7 breast cancers, in MDA-MB231 and MDA-MB468 and in HCC-1937 (BRCA 1 mutated) and HCC-1806 TNBC cells. Expression of pAKT, B7H1 and infiltration with Tregs were determined by immunohistochemistry in human specimens of benign and malignant breast disease.
RESULTS: NK-cell induced lysis was significantly increased (p < 0.05) in four TNBC cell lines compared to ER + MCF 7 cells. Fibroadenomas and mastectomy samples were not infiltrated with Tregs. Infiltration with Tregs was 0.92 ± 0.21 in ER/PR + breast cancers and significantly higher in TNBC without (2.30 ± 0.34) and also significantly higher with mutation of BRCA 1 (2.10 ± 0.34). Expression of pAKT was absent in benign controls and 1.23 ± 0.36 in ER/PR + breast cancers, 1.78 ± 0.40 in TNBC without and 2.40 ± 0.30 with mutated BRCA 1. No significant differences of B7H1 expression occurred among the breast cancer subgroups.
CONCLUSION: TNBC cell stimulate the NK-cell immune response significantly stronger than ER positive breast cancer cells. This could explain why infiltration with immunosuppressive Tregs is increased in human specimens of TNBC with and without mutated BRCA 1. Accordingly, immunomodulatory treatment strategies should be further explored in TNBC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23828443     DOI: 10.1007/s00404-013-2922-9

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  17 in total

1.  Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium.

Authors:  Brian C Willis; Emily A Sloan; Kristen A Atkins; Mark H Stoler; Anne M Mills
Journal:  Mod Pathol       Date:  2017-07-28       Impact factor: 7.842

Review 2.  The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers.

Authors:  Qingli Jiao; Aiguo Wu; Guoli Shao; Haoyu Peng; Mengchuan Wang; Shufeng Ji; Peng Liu; Jian Zhang
Journal:  J Thorac Dis       Date:  2014-09       Impact factor: 2.895

3.  Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer.

Authors:  Minya Yao; Yu Liu; Hailong Jin; Xiaojiao Liu; Kezhen Lv; Haiyan Wei; Chengyong Du; Shuqian Wang; Bajin Wei; Peifen Fu
Journal:  Onco Targets Ther       Date:  2014-09-26       Impact factor: 4.147

4.  MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells.

Authors:  Christian Breunig; Jens Pahl; Moritz Küblbeck; Matthias Miller; Daniela Antonelli; Nese Erdem; Cornelia Wirth; Rainer Will; Alexander Bott; Adelheid Cerwenka; Stefan Wiemann
Journal:  Cell Death Dis       Date:  2017-08-03       Impact factor: 8.469

5.  Gene regulatory pattern analysis reveals essential role of core transcriptional factors' activation in triple-negative breast cancer.

Authors:  Li Min; Cheng Zhang; Like Qu; Jialiang Huang; Lan Jiang; Jiafei Liu; Luca Pinello; Guo-Cheng Yuan; Chengchao Shou
Journal:  Oncotarget       Date:  2017-03-28

Review 6.  Mechanism of immune evasion in breast cancer.

Authors:  Mozhi Wang; Changwang Zhang; Yongxi Song; Zhenning Wang; Yaojia Wang; Fang Luo; Yujie Xu; Yi Zhao; Zhonghua Wu; Yingying Xu
Journal:  Onco Targets Ther       Date:  2017-03-14       Impact factor: 4.147

7.  Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2.

Authors:  Ralf Kleef; Ralph Moss; A Marcell Szasz; Arthur Bohdjalian; Hans Bojar; Tibor Bakacs
Journal:  Integr Cancer Ther       Date:  2018-09-07       Impact factor: 3.279

8.  The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells.

Authors:  Bo Yuan Huang; Yi Ping Zhan; Wen Jing Zong; Chun Jiang Yu; Jun Fa Li; Yan Ming Qu; Song Han
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

9.  The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients.

Authors:  Weijuan Jia; Jiannan Wu; Haixia Jia; Yaping Yang; Xiaolan Zhang; Kai Chen; Fengxi Su
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

10.  A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma.

Authors:  Hiroyuki Kanzaki; Fumiaki Shinohara; Maiko Suzuki; Satoshi Wada; Yutaka Miyamoto; Yuuki Yamaguchi; Yuta Katsumata; Seicho Makihira; Toshi Kawai; Martin A Taubman; Yoshiki Nakamura
Journal:  Sci Rep       Date:  2016-08-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.